Related Experiment Video
Updated: Dec 1, 2025

07:47
Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies
Published on: September 15, 2023
2.0K
Tumor Mutational Burden as a Pan-cancer Biomarker for Immunotherapy: The Limits and Potential for Convergence
Antonio Passaro1, Albrecht Stenzinger2, Solange Peters3
1Division of Thoracic Oncology, European Institute of Oncology, IRCCS, Milan, Italy.
Cancer Cell
|November 10, 2020
Abstract:
A recent study in The Lancet Oncology reports that high tumor mutational burden (TMB) is associated with response to anti-PD-1 pembrolizumab, leading to the second FDA approval of a tissue-agnostic predictive biomarker for immunotherapy in solid tumors. This is a step forward in realizing the full potential of cancer immunotherapy.

